D3A.09 Categoría · se requiere mayor especificidad Benign carcinoid tumors of other sites
ICD-10-CM D3A.09 identifies “Benign carcinoid tumors of other sites” as a category requiring further specificity in the FY2027 U.S. classification, effective October 1, 2026 through September 30, 2027.
Capítulo 2: Neoplasms
Instrucciones del código
Sin notas adicionales.
Instrucciones de niveles superiores
D3A · Benign neuroendocrine tumors
Excludes 21
benign pancreatic islet cell tumors (D13.7)
Use additional code2
- code to identify any associated endocrine syndrome, such as:
- carcinoid syndrome (E34.00)
Code also1
any associated multiple endocrine neoplasia [MEN] syndromes (E31.2-)
Capítulos 2 · Neoplasms (C00-D49)
Note8
- Functional activity
- All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
- Morphology [Histology]
- Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
- Primary malignant neoplasms overlapping site boundaries
- A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
- Malignant neoplasm of ectopic tissue
- Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
Códigos más específicos
D3A.090Benign carcinoid tumor of the bronchus and lungCódigo facturable y específicoD3A.091Benign carcinoid tumor of the thymusCódigo facturable y específicoD3A.092Benign carcinoid tumor of the stomachCódigo facturable y específicoD3A.093Benign carcinoid tumor of the kidneyCódigo facturable y específicoD3A.094Benign carcinoid tumor of the foregut, unspecifiedCódigo facturable y específicoD3A.095Benign carcinoid tumor of the midgut, unspecifiedCódigo facturable y específicoD3A.096Benign carcinoid tumor of the hindgut, unspecifiedCódigo facturable y específicoD3A.098Benign carcinoid tumors of other sitesCódigo facturable y específicoReferencias del índice oficial
Historial
Historial del código
Último cambio registrado · FY2025
ModificadoSin cambios
FY2025
Vigente desde
- Cambios en instrucciones heredadas
Benign carcinoid tumors of other sites
Categoría — seleccione un código más específico
CDC/NCHS · FY2025Todas las ediciones (19)
| Todas las ediciones | Vigente desde | Historial del código |
|---|---|---|
| FY2016 | 2015-10-01 | Primera aparición |
| FY2017 | 2016-10-01 | Sin cambios tabulares |
| FY2018 | 2017-10-01 | Sin cambios tabulares |
| FY2019 | 2018-10-01 | Sin cambios tabulares |
| FY2020 | 2019-10-01 | Sin cambios tabulares |
| FY2020 · April | 2020-04-01 | Sin cambios tabulares |
| FY2021 | 2020-10-01 | Sin cambios tabulares |
| FY2021 · 01-01 | 2021-01-01 | Sin cambios tabulares |
| FY2022 | 2021-10-01 | Sin cambios tabulares |
| FY2022 · 04-01 | 2022-04-01 | Sin cambios tabulares |
| FY2023 | 2022-10-01 | Sin cambios tabulares |
| FY2023 · 04-01 | 2023-04-01 | Sin cambios tabulares |
| FY2024 | 2023-10-01 | Sin cambios tabulares |
| FY2024 · 04-01 | 2024-04-01 | Sin cambios tabulares |
| FY2025 | 2024-10-01 | Cambios en instrucciones heredadas |
| FY2025 · 04-01 | 2025-04-01 | Sin cambios tabulares |
| FY2026 | 2025-10-01 | Sin cambios tabulares |
| FY2026 · April | 2026-04-01 | Sin cambios tabulares |
| FY2027 | 2026-10-01 | Sin cambios tabulares |
Explora los códigos más específicos de esta categoría. La comprobación del catálogo no establece la pertinencia clínica ni garantiza el reembolso.